Begin Your Search

If you know the name of a drug manufacturer, you can easily search using the alphabetical menu below. Or you can search in free text – simply type the disease, drug, company name, or other detail into the Search bar below and click on the magnifying glass. For broadest results, type the terms without quotation marks; to narrow your search to an exact match, put your terms in quotation marks (i.e.; “breast cancer”). See Search Tips for tips and definitions to make your searches more effective.

The web links in this directory are public information provided to the Foundation and the acknowledgement times listed are the number of days or hours for a company to acknowledge receipt of request, not to make a decision. Data contained in this directory is provided either directly by the company or by ClinicalTrials.gov for the companies listed in this directory.

The Expanded Access listings provided on this website are limited to those companies currently in the Company Directory and include listings for expanded access which are Available, Temporarily Not Available and Approved for Marketing, which in some cases includes treatments which have not yet reached the market. In addition, many companies are willing to consider expanded access requests even if they do not show active Expanded Access Listings in this directory. Contact the company to explore the possibility of individual access to an investigational therapy.

To learn more about clinical trials and expanded access, please visit our patient and physician guides on this website.

4 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Company Name
Phone Number & Email
Company Acknowledgement

Faron Pharmaceuticals Ltd

EA Webpage Clinicaltrials.gov
Phone Number & Email
Expected Application Timeframe
3 business days
Single-Patient EA Policies/Criteria

General Policy
Faron Pharmaceuticals does not have an open Expanded Access program at this time. Participation in one of our ongoing clinical trials is the most appropriate way to access bexmarilimab and other investigational therapies. We encourage patients to speak with their physicians about the possibility of enrolling in a clinical trial listed on ClinicalTrials.gov.

Revisions to the Policy
Consistent with the 21st Century Cures Act, Faron Pharmaceuticals may revise this policy at any time without prior notice. Updates to the policy will be made available on this directory, our website and through appropriate communication channels.

Forte Biosciences, Inc.

EA Webpage Clinicaltrials.gov
Phone Number & Email
Expected Application Timeframe
N/A
Single-Patient EA Policies/Criteria

Expanded access, also called “compassionate use”, enables some patients with an immediately life-threatening condition or serious disease to gain access to an investigational new drug for treatment outside of clinical trials when no alternative therapy options are available. Currently, Forte does not offer an expanded access program. Forte may revise this policy at any time.

Disease/Category-Specific EA Policies/Criteria

https://www.fortebiorx.com/pipeline/default.aspx

Frontier Biotechnologies Inc.

EA Webpage Clinicaltrials.gov
Phone Number & Email
Expected Application Timeframe
10 business days
Single-Patient EA Policies/Criteria

The IND has been deemed safe-to-proceed and the fast track designation has been granted. The registration in ClinicalTrials.gov will be done before the trial starts and a link will be provided then.

FUJIFILM Pharmaceuticals U.S.A., Inc.

EA Webpage Clinicaltrials.gov
Single-Patient EA Policies/Criteria

Currently, FUJIFILM Pharmaceuticals U.S.A., Inc. is not accepting expanded access/compassionate use requests.

Displaying 4 companies